ALLMedicine™ Hepatic Encephalopathy Center

Jan 16th, 2022 - The Controlling Nutritional Status (CONUT) score is designed to assess the immune-nutritional status of patients. Poor nutritional status and inflammation may facilitate the development of hepatic encephalopathy (HE) in cirrhotic patients. However...

Jan 15th, 2022 - Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a life-threatening disease with high short-term mortality. Early and accurate prognosis is significant for clinical decision, in which liver volume (LV) impart important inform...

Jan 14th, 2022 - A 54-year-old man with hepatocellular carcinoma from alcohol-induced cirrhosis presented with hepatic encephalopathy and refractory ascites related to decompensated liver disease. MRI confirmed disease progression adjacent the site of prior radiof...

Jan 13th, 2022 - To develop and evaluate a machine learning-based CT radiomics model for the prediction of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS). A total of 106 patients who underwent TIPS placement were consecutive...

Jan 13th, 2022 - Rifaximin use in combination with lactulose is associated with a decreased risk of overt hepatic encephalopathy (HE). We prospectively evaluated the impact of an interruptive electronic medical record alert to indicate rifaximin for patients with ...

Jan 11th, 2020 - KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.|2020| ,|

Oct 3rd, 2019 - The Chinese Society of Hepatology developed the current guidelines on the management of hepatic encephalopathy in cirrhosis based on the published evidence and the panelists' consensus. The guidelines provided recommendations for the diagnosis and...

Sep 6th, 2017 - Some patients with veno-occlusive disease (VOD) have multiorgan dysfunction, and multiple teams are involved in their daily care in the pediatric intensive care unit. Cardiorespiratory dysfunction is critical in these patients, requiring immediate...

Nov 26th, 2015 - Hepatic encephalopathy is defined as brain dysfunction caused by liver insufficiency and/or portosystemic shunting. Symptoms include nonspecific cognitive impairment, personality changes and changes in consciousness. Overt (symptomatic) hepatic en...

Feb 11th, 2011 - The clinical classification of hepatic encephalopathy is largely subjective, which has led to difficulties in designing trials in this field. To review the current classification of hepatic encephalopathy and to develop consensus guidelines on the...

Jan 5th, 2022 - A total of 40 patients taking proton pump inhibitors (PPIs) who undergo transjugular intrahepatic portosystemic shunt (TIPS) creation as part of routine clinical care will be randomized in 1:1 fashion to either continue or discontinue their PPIs t...

Dec 17th, 2021 - This study aims to improve cognition and function in patients with Alzheimer's Disease (AD) by administering the oral antibiotic, rifaximin. Rifaximin is a virtually non-absorbed antibiotic with the unique properties of altering gut microbiota and...

Dec 15th, 2021 - The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.

Dec 14th, 2021 - Globally, the mortality after any infection in cirrhosis patients is very high. The cumulative mortality in patients with infections was 43.5% (11,987 patients) where as the mortality rate without infection was 13.6% (2317 patients). Over the year...

Dec 2nd, 2021 - For the prevention of recurrent esophageal variceal bleeding, previous clinical studies and meta-analysis show that patients treated with transjugular intrahepatic portosystemic shunt (TIPS) have lower rebleeding rates compared with endoscopic the...

Sep 2nd, 2021 - Tanios S. Bekaii-Saab, MD, FACP: Anjana, one of the most confusing elements, but one that has been ingrained so heavily into how we select patients for therapies is how we score liver function, and we still rely on a system from the 1970s. Give an...

Jul 14th, 2021 - Ruben Mesa, MD, FACP: We had a new drug developed and approved in 2019. We’ve had an updated analysis that’s giving us a framework of the role of fedratinib in the frontline and second-line settings. Pankit, why don’t you share with us a bit? What...

Jul 1st, 2021 - Dear colleagues and friends, The Perspectives series continues! There are few issues in our discipline that are as challenging, and controversial, as liver transplant prioritization. The Model for End-Stage Liver Disease (MELD) has been the mainst.

Apr 2nd, 2021 - Transcript: Richard S. Finn, MD: Alpha-fetoprotein [AFP] has been around for a long time, right? How do you approach the use of AFP in diagnosing patients with liver cancer? Pierre Gholam, MD: As an AFP enthusiast, we have had a love-hate re...

Apr 2nd, 2021 - Transcript: Peter Galle, MD: The history goes in a way that until 2002, when we had the definition of TACE [trans-arterial chemoembolization] as a successful treatment, we basically had surgery. That was transplantation, resection, and not muc...